Retrospective TMS Therapy for Adults With MDD

Status Completed

Clinical Trial Summary

Examine change in the magnitude of antidepressant effects as a function of number of TMS sessions and to determine whether extended treatment courses, beyond 30 and beyond 36 TMS sessions, result in improved efficacy.

Clinical Trial Description

The efficacy of TMS in major depressive disorder (MDD) has markedly improved since the pivotal sham-controlled trials. While this enhanced efficacy has been attributed to use of longer treatment courses, the impact of number of treatment sessions on efficacy has not been adequately evaluated. The study device is the Neuronetics, Inc. NeuroStar® TMS Therapy System (K160703, K201158).The study is a retrospective analysis of real-world data from commercial centers. The data will be gathered from the Neuronetics database called TrakStar which collects records of each patient's treatment. The data will be used only as applicable to the objectives of this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05541302
Study type	Observational
Source	Neuronetics
Contact
Status	Completed
Phase
Start date	November 1, 2008
Completion date	August 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00316160` - Sexual Functioning Study With Antidepressants	Phase 4
Completed	`NCT05416957` - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets	Phase 1
Active, not recruiting	`NCT03642964` - A Study in Patients With Major Depressive Disorder	Phase 2
Terminated	`NCT01111565` - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)	Phase 3
Completed	`NCT01912196` - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)	Phase 2
Completed	`NCT00958204` - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression	Phase 3
Completed	`NCT00102492` - Study Of GW679769 In Major Depressive Disorder	Phase 2
Completed	`NCT02012218` - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy	Phase 3
Completed	`NCT01477203` - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders	Phase 4
Completed	`NCT00768430` - Optimization of IV Ketamine for Treatment Resistant Depression	Phase 2
Completed	`NCT00559299` - Patient Tolerability Study of GSK163090	Phase 1
Terminated	`NCT01123707` - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)	Phase 3
Completed	`NCT04403373` - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study	N/A
Recruiting	`NCT06385405` - Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment	N/A
Completed	`NCT00330616` - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan	Phase 2
Recruiting	`NCT03012724` - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)	N/A
Completed	`NCT02380066` - Comparison of Anyu Peibo With Placebo in Treatment of MDD	Phase 2
Not yet recruiting	`NCT02395263` - Comparison of Yuxintine With Placebo in Treatment of MDD	Phase 2
Completed	`NCT01187407` - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment	Phase 3
Completed	`NCT00448292` - A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder	Phase 2